Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase IB/IIA, Open-Label Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of Fosciclopirox Alone And In Combination With Cytarabine In Patients With Relapsed/Refractory Acute Myeloid Leukemia
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Study Type: Treatment
Phase: III
NCTID: NCT02521493
Principal Investigator:
Keith August
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia.
A Phase I, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination with ASTX727 in Subjects with Acute Myeloid Leukemia
A Phase IB/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination with Cytarabine and Daunorubicin in Patients Newly Diagnosed with Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
A Phase Ib/II Open-Label Study of APVO436 in Combination with Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia AML
Study Type: Treatment
Phase: I/II
NCTID: NCT06634394
Principal Investigator:
Tara Lin
Phase I Study of Escalating Single and Multiple Doses of Mana 312 Multi Tumor-Associated Antigen T cells Administered to Adult Subjects with Acute Myeloid Leukemia or Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplant
Study Type: Treatment
Phase: I
NCTID: NCT04679194
Principal Investigator:
Haitham Abdelhakim
An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT04203316
Principal Investigator:
Kevin Ginn